Simcere Secures NMPA Approval for CDH17‑Targeting ADC SIM0609 in Advanced Solid Tumors
CompanyDrug

Simcere Secures NMPA Approval for CDH17‑Targeting ADC SIM0609 in Advanced Solid Tumors

DaAnGene Secures NMPA Approval for First HIVDNA Diagnostic Kit
CompanyMedical Device

DaAn Gene Secures NMPA Approval for First HIVDNA Diagnostic Kit

NMPA Releases Online Prescription Compliance Guidelines to Tighten Drug Retail Oversight
Policy / Regulatory

NMPA Releases Online Prescription Compliance Guidelines to Tighten Drug Retail Oversight

Sirnaomics Secures HK$138 M Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines
CompanyDeals

Sirnaomics Secures HK$138 M Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines

RemeGen Secures China CDE Approval for Telitacicept in Sjögren’s Syndrome, First Biologic of Its Kind
CompanyDrug

RemeGen Secures China CDE Approval for Telitacicept in Sjögren’s Syndrome, First Biologic of Its Kind

Shanghai Henlius Biotech Secures FDA IND Approval for HLX17, a Pembrolizumab Biosimilar
CompanyDrug

Shanghai Henlius Biotech Secures FDA IND Approval for HLX17, a Pembrolizumab Biosimilar

Kintor Pharmaceutical Completes KT‑939 Tyrosinase Inhibitor Safety Trial, Highlights Cosmetic Potential
CompanyDrug

Kintor Pharmaceutical Completes KT‑939 Tyrosinase Inhibitor Safety Trial, Highlights Cosmetic Potential

Grand Pharma Secures CE Mark for SIR‑Spheres Y‑90, Expanding Liver‑Cancer Treatment Portfolio
CompanyDrug

Grand Pharma Secures CE Mark for SIR‑Spheres Y‑90, Expanding Liver‑Cancer Treatment Portfolio

Chongqing Genrix Bio Secures NMPA Approval for GR2303, a Novel TL1A‑Targeting Antibody in IBD
CompanyDrug

Chongqing Genrix Bio Secures NMPA Approval for GR2303, a Novel TL1A‑Targeting Antibody in IBD

Fosun Pharma Secures Foritinib Approval for ALK‑NSCLC Trials, Paving Way for Targeted Therapy
CompanyDrug

Fosun Pharma Secures Foritinib Approval for ALK‑NSCLC Trials, Paving Way for Targeted Therapy

Duality Biotherapeutics Hits PFS Milestone with DB‑1303/BNT323 in HER2‑Positive Breast Cancer
CompanyDrug

Duality Biotherapeutics Hits PFS Milestone with DB‑1303/BNT323 in HER2‑Positive Breast Cancer

Innovent Biologics Announces Strong Phase II Results for Tigulixostat in Chinese Gout Patients
CompanyDrug

Innovent Biologics Announces Strong Phase II Results for Tigulixostat in Chinese Gout Patients